Glybuthiazol

This classification denotes an anti-diabetic agent with the molecular formula C12H16N4O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 35421N8E8W, chemically known as sulfanilamide, n(sup 1)-(5-tert-butyl-1,3,4-thiadiazol-2-yl)- but more generally known as glybuthiazol, which bears US NIH Compound Identifier 10811. European Medicines Agency schedules Glybuthiazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07946MIG. The term GLYBUTHIAZOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). GLYBUTHIAZOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule glybuthiazol under HS 29350090 and SITC 51580. As of Q4 2014, GLYBUTHIAZOL remains US FDA's Preferred Term for this commodity. Glybuthiazol bears US NLM identifiers UMLS ID C2348868 and NCI Concept Code C72803. SMILES: CC(C)(C)C1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N.